These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19666254)

  • 41. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children.
    Goldman CG; Barrado DA; Balcarce N; Rua EC; Oshiro M; Calcagno ML; Janjetic M; Fuda J; Weill R; Salgueiro MJ; Valencia ME; Zubillaga MB; Boccio JR
    Nutrition; 2006 Oct; 22(10):984-8. PubMed ID: 16978844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Antimicrobial resistance of Helicobacter pylori: clinical and molecular aspects].
    Vallejos C; Cerda O; Valenzuela M; Toledo H
    Rev Med Chil; 2003 Nov; 131(11):1313-20. PubMed ID: 14743695
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The cause of failure of eradication treatment of Helicobacter pylori].
    Chen G; Takeuchi Y; Kikuchi R; Arai D; Fukuchi K; Gomi K
    Rinsho Byori; 2005 Aug; 53(8):692-7. PubMed ID: 16190353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].
    Díte P; Kunovská M; Pulgretová D; Woznica V; Petrtýl J; Hůlek P; Pásková J; Dostalík Z; Novotný I; Procházka V; Hegyi P; Zelenková J; Samek M; Králová Z; Vyhnálek P; Matejovic F; Weinberg J; Kyzeková J
    Vnitr Lek; 2002 Oct; 48(10):976-80. PubMed ID: 16737149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate.
    Yoon H; Kim N; Lee BH; Hwang TJ; Lee DH; Park YS; Nam RH; Jung HC; Song IS
    Helicobacter; 2009 Oct; 14(5):77-85. PubMed ID: 19751431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Helicobacter pylori eradication: a critical appraisal and current concerns.
    Hunt RH
    Scand J Gastroenterol Suppl; 1995; 210():73-6. PubMed ID: 8578213
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Gastroduodenal diseases and Helicobacter pylori infection: overview].
    Tsimmerman IaS
    Klin Med (Mosk); 2009; 87(5):9-15. PubMed ID: 19565820
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting Helicobacter pylori eradication: how to teach an old dog new tricks!
    Zullo A; De Francesco V; Hassan C
    J Clin Gastroenterol; 2012 Apr; 46(4):259-61. PubMed ID: 22395061
    [No Abstract]   [Full Text] [Related]  

  • 50. Sequential therapy for H. pylori eradication.
    Drug Ther Bull; 2011 Sep; 49(9):102-5. PubMed ID: 21921072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New strategies for Helicobacter pylori eradication.
    Selgrad M; Malfertheiner P
    Curr Opin Pharmacol; 2008 Oct; 8(5):593-7. PubMed ID: 18555746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sucralfate and Helicobacter pylori.
    Terano A; Shimada T; Hiraishi H
    J Gastroenterol; 1996 Nov; 31 Suppl 9():63-5. PubMed ID: 8959523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of probiotics in Helicobacter pylori eradication therapy.
    Medeiros JA; Pereira MI
    J Clin Gastroenterol; 2013 Jan; 47(1):1-5. PubMed ID: 23222208
    [No Abstract]   [Full Text] [Related]  

  • 54. 7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
    Antos D; Schneider-Brachert W; Bästlein E; Hänel C; Haferland C; Buchner M; Meier E; Trump F; Stolte M; Lehn N; Bayerdörffer E
    Helicobacter; 2006 Feb; 11(1):39-45. PubMed ID: 16423088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection.
    Furuta T; Graham DY
    Gastroenterol Clin North Am; 2010 Sep; 39(3):465-80. PubMed ID: 20951912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of Helicobacter pylori infection 2011.
    O'Connor A; Gisbert JP; McNamara D; O'Morain C
    Helicobacter; 2011 Sep; 16 Suppl 1():53-8. PubMed ID: 21896086
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.
    Fiorini G; Vakil N; Zullo A; Saracino IM; Castelli V; Ricci C; Zaccaro C; Gatta L; Vaira D
    Clin Gastroenterol Hepatol; 2013 May; 11(5):507-10. PubMed ID: 23267869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The minutes of Maastricht-Ⅴconsensus conference and the fifth Chinese
    Xie C; Lyu NH
    Zhonghua Nei Ke Za Zhi; 2017 Mar; 56(3):216-217. PubMed ID: 28253606
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapy of helicobacter pylori infection].
    Kubisch CH; Gross MM
    MMW Fortschr Med; 2015 Jul; 157(13):43-5. PubMed ID: 26206036
    [No Abstract]   [Full Text] [Related]  

  • 60. Helicobacter pylori Treatment Failure: The Rationale for Alternative Antibiotics.
    O''Morain C; Smith S
    Digestion; 2016; 93(4):309-10. PubMed ID: 27246467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.